Multiple Sclerosis: Disease-Modifying Therapy Selection Algorithm

Progressive MS: Limited but Expanding Options

Ocrelizumab is the only approved therapy for primary progressive MS (PPMS), with the ORATORIO trial demonstrating a 24% reduction in 12-week confirmed disability progression[8]. Siponimod is approved for active secondary progressive MS (SPMS) based on the EXPAND trial (21% disability progression reduction)[9]. For progressive MS without active inflammation, no approved therapy demonstrates robust benefit. Neurodegenerative disease management parallels challenges seen in Alzheimer's disease treatment. Emerging evidence suggests anti-CD20 therapies are most effective in progressive MS patients who still have MRI inflammatory activity or are younger (under 55).

Practical Selection Algorithm

For treatment-naive relapsing MS with poor prognostic factors (high lesion burden, spinal cord lesions, frequent relapses, young age at onset), initiate early high-efficacy therapy with ocrelizumab or natalizumab (if JCV-negative). For lower-risk patients or those preferring oral therapy, dimethyl fumarate, teriflunomide, or S1P modulators are reasonable. Monitor all patients with annual MRI and clinical assessment. Evidence of breakthrough disease (new T2 lesions, gadolinium enhancement, clinical relapse, or disability worsening) on a moderate-efficacy DMT warrants escalation to a high-efficacy agent without delay.

Talking to Patients About Treatment Decisions

MS treatment decisions are among the most complex shared decision-making conversations in neurology. Patients are often young, newly diagnosed, and overwhelmed — asked to choose between therapies with different routes of administration, monitoring requirements, and risk profiles. The clinician's role is to translate the efficacy and safety data into terms that matter to the individual patient: How often do I need to come in for infusions or lab work? What are the most common day-to-day side effects? What is the worst-case safety scenario, and how rare is it? For patients with aggressive disease features who are candidates for early high-efficacy therapy, the conversation should be explicit: starting with a more potent therapy now, before irreversible disability accumulates, offers the best chance of long-term outcomes — even though the monitoring and risk profile are more intensive than starting with a moderate-efficacy oral agent.

Limitations and Evolving Questions

The early high-efficacy therapy paradigm is supported by growing evidence but remains a matter of clinical judgment rather than definitive randomized proof — the DELIVER-MS and TREAT-MS trials provide important data but are not yet practice-defining in the way that large outcomes trials have been in cardiology. The optimal duration of DMT is unknown: whether patients on long-term anti-CD20 therapy can eventually discontinue and maintain remission is an active area of investigation. Progressive MS remains a therapeutic frontier where available options provide modest benefit at best, and where the distinction between inflammatory and neurodegenerative components of the disease dictates which patients might respond to current immunomodulatory approaches.

References

1. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
2. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
3. PML risk stratification by JC virus antibody index
4. NOVA study: natalizumab extended interval dosing and PML risk
5. Ofatumumab versus Teriflunomide in Multiple Sclerosis
6. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis (DEFINE)
7. Randomized trial of oral teriflunomide for relapsing multiple sclerosis (TEMSO)
8. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
9. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study